Biomarin Pharmaceutical (BMRN) Net Equity Issued and Repurchased (2012 - 2015)

Biomarin Pharmaceutical's Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $888.3 million for Q1 2015.

• Quarterly Net Equity Issued and Repurchased rose 655.96% year-over-year to $888.3 million in Q1 2015, while the trailing twelve-month figure through Dec 2015 was $888.3 million (up 656.2% YoY) and the FY2016 annual result came in at $712.9 million, down 19.74% from the prior year.
• Net Equity Issued and Repurchased was $888.3 million for Q1 2015 at Biomarin Pharmaceutical, up from -$36000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $888.3 million in Q1 2015 and bottomed at -$36000.0 in Q2 2014.
• A 3-year average of $310.3 million and a median of $176.5 million in 2012 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 655.96% in 2015, while the deepest fall reached 655.96% in 2015.
• Biomarin Pharmaceutical's Net Equity Issued and Repurchased stood at $235.5 million in 2012, then slumped by 100.02% to -$36000.0 in 2014, then soared by 2467480.56% to $888.3 million in 2015.
• Business Quant data shows BMRN's Net Equity Issued and Repurchased at $888.3 million in Q1 2015, -$36000.0 in Q2 2014, and $117.5 million in Q1 2014.